Form 4: Emergent BioSolutions Director Marvin L. White Acquires Shares and Stock Options

Director Marvin L. White reports acquisition of Emergent BioSolutions stock and stock options as part of annual compensation.

Summary

• Marvin L. White, a director of Emergent BioSolutions Inc., reported the acquisition of 17,430 shares of common stock and 25,748 stock options on May 23, 2024.
• The shares were acquired as restricted stock units (RSUs) granted under the company's Stock Incentive Plan for Board and Committee service.
• The stock options were also granted under the Stock Incentive Plan for Board and Committee service, with an exercise price of $5.02.
• The RSUs and stock options vest on the day prior to the one-year anniversary of the grant date, contingent upon the reporting person remaining a member of the company's board of directors.
• Following the reported transaction, White beneficially owns 68,379 shares of common stock and 25,748 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction related to director compensation, indicating a neutral to slightly positive sentiment as it aligns director interests with the company's performance.

Positives

• The grant of RSUs and stock options aligns the director's interests with those of the company and its shareholders.
• The vesting requirements incentivize continued service on the board of directors.
• The acquisition of shares demonstrates the director's confidence in the company's future prospects.

Future Outlook

The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.

Industry Context

This filing is a routine disclosure related to director compensation and is typical for publicly traded companies. It reflects standard practices for incentivizing board members.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are common across publicly traded companies, particularly in the biotechnology sector.
• Companies like Moderna, Pfizer, and BioNTech also utilize similar equity-based compensation to align director and shareholder interests.
• The vesting schedules and terms outlined in this filing are generally consistent with industry norms for director compensation.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders by aligning director interests with company performance.
• The compensation structure incentivizes the director to contribute to the company's long-term success.

Key Dates